UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000034251
Receipt No. R000039041
Scientific Title Prediction of the pharmacokinetics and adverse events of glecaprevir/pibrentasvir in patients with hepatitis C virus by gadoxetic acid enhanced magnetic resonance imaging
Date of disclosure of the study information 2018/09/25
Last modified on 2018/09/24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Prediction of the pharmacokinetics and adverse events of glecaprevir/pibrentasvir in patients with hepatitis C virus by gadoxetic acid enhanced magnetic resonance imaging
Acronym Prediction of the PKs and AEs of GLE/PIB by EOB-MRI
Scientific Title Prediction of the pharmacokinetics and adverse events of glecaprevir/pibrentasvir in patients with hepatitis C virus by gadoxetic acid enhanced magnetic resonance imaging
Scientific Title:Acronym Prediction of the PKs and AEs of GLE/PIB by EOB-MRI
Region
Japan

Condition
Condition Type C chronic hepatitis or type C liver cirrhosis
Classification by specialty
Hepato-biliary-pancreatic medicine Psychosomatic Internal Medicine
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To determine whether enhancement effect of gadoxetic acid magnetic resonance imaging can predict the blood concentration of glecaprevir and adverse events
Basic objectives2 Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes To clarify the relationship between the pretreatment enhancement effect of Gd-EOB-DTPA MRI and the plasma glecaprevir concentration determined 7 days after its administration
Key secondary outcomes To clarify the relationship between enhancement effect of Gd-EOB-DTPA MRI and development of hyperbilirubinemia during treatment.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) chronic hepatitis C or compensated liver cirrhosis C patients using glecaprevir and pibrentasvir
Key exclusion criteria 1) Hypersensitivity to Gd-EOB-DTPA
2) Estimated glomerular filtration rate under 40ml/min/1.73m2
Target sample size 60

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Hironao Okubo
Organization Juntendo University Nerima Hospital
Division name Department of gastroenterology
Zip code
Address 3-1-10 Takanodai, Nerima-Ku Tokyo, Japan
TEL +81-3-5923-3111
Email drokubo@juntendo-nerima.jp

Public contact
Name of contact person
1st name
Middle name
Last name Hironao Okubo
Organization Juntendo University Nerima Hospital
Division name Department of gastroenterology
Zip code
Address 3-1-10 Takanodai, Nerima-Ku Tokyo, Japan
TEL +81-3-5923-3111
Homepage URL
Email drokubo@juntendo-nerima.jp

Sponsor
Institute Juntendo University Nerima Hospital
Institute
Department

Funding Source
Organization Self funding
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 09 Month 25 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2018 Year 08 Month 06 Day
Date of IRB
Anticipated trial start date
2018 Year 09 Month 25 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information None

Management information
Registered date
2018 Year 09 Month 24 Day
Last modified on
2018 Year 09 Month 24 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039041

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.